The distinction between TP53‐mutant MDS versus AML using the time‐honored World Health Organization (WHO) blast cutoff of 20% is arbitrary, and very recent studies have shown negligible differences in both genetic profiles and clinical outcomes between MDS and AML [11]. The gene discussed is TP53; the disease is acute myeloid leukemia.